Pyridine-based small molecule inhibitors of SARM1 alleviate cell death caused by NADase activity

被引:0
|
作者
Tang, Qingxuan [1 ,2 ,3 ,4 ,5 ]
Yin, Hang [1 ,2 ,3 ,4 ,5 ]
机构
[1] Tsinghua Univ, State Key Lab Membrane Biol, Beijing 100084, Peoples R China
[2] Tsinghua Univ, Sch Pharmaceut Sci, Beijing 100084, Peoples R China
[3] Tsinghua Univ, Tsinghua Peking Ctr Life Sci, Beijing 100084, Peoples R China
[4] Tsinghua Univ, Minist Educ, Key Lab Bioorgan Phosphorous Chem & Chem Biol, Beijing 100084, Peoples R China
[5] Peking Univ, Tsinghua Univ, Natl Inst Biol Sci Joint Grad Program, Beijing 100084, Peoples R China
基金
中国国家自然科学基金;
关键词
NAD(+) CLEAVAGE ACTIVITY; INJURY; ACTIVATION; DELETION; MODELS;
D O I
10.1039/d4cc02650k
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Our investigation has unveiled a series of pyridine-based SARM1 inhibitors, with the lead compound TH-408 exhibiting remarkable potency, achieving an IC50 value of 0.46 mu M. This exceptional inhibitory effect significantly curtailed SARM1-mediated cell death across diverse biological models. This finding highlights the promising therapeutic potential for neurodegenerative disorders by disrupting SARM1 activation and advances our understanding of molecular interventions in these complex disorders, including the regulation of NAD+ metabolism. TH-408 counters toxicity by inhibiting SARM1 activation and NAD+ depletion, offering a promising approach to cell death prevention.
引用
收藏
页码:8724 / 8727
页数:4
相关论文
共 50 条
  • [41] Systems biology approaches based discovery of a small molecule inhibitor targeting both c-Met/PARP-1 and inducing cell death in breast cancer
    Yu, Tian
    Cheng, Lijia
    Yan, Xueling
    Xiong, Hang
    Chen, Jie
    He, Gang
    Zhou, Hui
    Dong, Hongbo
    Xu, Guangya
    Tang, Yong
    Shi, Zheng
    JOURNAL OF CANCER, 2020, 11 (09): : 2656 - 2666
  • [42] Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
    Leverson, J. D.
    Zhang, H.
    Chen, J.
    Tahir, S. K.
    Phillips, D. C.
    Xue, J.
    Nimmer, P.
    Jin, S.
    Smith, M.
    Xiao, Y.
    Kovar, P.
    Tanaka, A.
    Bruncko, M.
    Sheppard, G. S.
    Wang, L.
    Gierke, S.
    Kategaya, L.
    Anderson, D. J.
    Wong, C.
    Eastham-Anderson, J.
    Ludlam, M. J. C.
    Sampath, D.
    Fairbrother, W. J.
    Wertz, I.
    Rosenberg, S. H.
    Tse, C.
    Elmore, S. W.
    Souers, A. J.
    CELL DEATH & DISEASE, 2015, 6 : e1590 - e1590
  • [43] Potent and selective small-molecule MCL-1 inhibitors demonstrate on-target cancer cell killing activity as single agents and in combination with ABT-263 (navitoclax)
    J D Leverson
    H Zhang
    J Chen
    S K Tahir
    D C Phillips
    J Xue
    P Nimmer
    S Jin
    M Smith
    Y Xiao
    P Kovar
    A Tanaka
    M Bruncko
    G S Sheppard
    L Wang
    S Gierke
    L Kategaya
    D J Anderson
    C Wong
    J Eastham-Anderson
    M J C Ludlam
    D Sampath
    W J Fairbrother
    I Wertz
    S H Rosenberg
    C Tse
    S W Elmore
    A J Souers
    Cell Death & Disease, 2015, 6 : e1590 - e1590
  • [44] Potent and Selective Small-Molecule Inhibitors of cIAP1/2 Proteins Reveal That the Binding of Smac Mimetics to XIAP BIR3 Is Not Required for Their Effective Induction of Cell Death in Tumor Cells
    Sun, Haiying
    Lu, Jianfeng
    Liu, Liu
    Yang, Chao-Yie
    Wang, Shaomeng
    ACS CHEMICAL BIOLOGY, 2014, 9 (04) : 994 - 1002
  • [45] Drug evaluation based on phosphomimetic PDHA1 reveals the complexity of activity-related cell death in A549 non-small cell lung cancer cells
    Jin, Ling
    Cho, Minkyoung
    Kim, Bo-Sung
    Han, Jung Ho
    Park, Sungmi
    Lee, In-Kyu
    Ryu, Dongryeol
    Kim, Jae Ho
    Bae, Sung-Jin
    Ha, Ki-Tae
    BMB REPORTS, 2021, 54 (11) : 563 - 568
  • [46] Re: Comments on 'High-intensity statins are associated with improved clinical activity of programmed cell death protein 1 inhibitors in malignant pleural mesothelioma and advanced non-small cell lung cancer patients'
    Cantini, Luca
    Pecci, Federica
    Dammeijer, Floris
    Aerts, Joachim G. J. V.
    Berardi, Rossana
    EUROPEAN JOURNAL OF CANCER, 2021, 153 : 267 - 269
  • [47] : Side-by-side comparison of small molecule IDO1 inhibitors in biochemical and cell-based assays and development of a ID01-expressing mouse model to evaluate target modulation
    Grobben, Yvonne
    Uitdehaag, Joost C. M.
    van Doornmalen, Antoon M.
    Willemsen-Seegers, Nicole
    Diep Vu-Pham
    de Man, Jos
    Buijsman, Rogier C.
    Zaman, Guido J. R.
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [48] Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials
    Ren, Wei
    Fang, Yingying
    He, Yujing
    Ren, Yifeng
    Wang, Minfang
    Xu, Anyi
    Ruan, Jiale
    Tao, Qinghua
    THERAPEUTIC DRUG MONITORING, 2024, 46 (04) : 422 - 433
  • [49] Clinical Response to Immune Checkpoint Inhibitors Is Associated With Response to Prior Platinum-based Chemotherapy in Non-small Cell Lung Cancer With Low or Negative Programmed Death Ligand-1 Expression
    Yeo, C.
    Kim, J.
    Lee, S.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2024, 209
  • [50] Different associations between organ-specific immune-related adverse event and survival in non-small cell lung cancer patients treated with programmed death-1 inhibitors-based combination therapy
    Chen, Yuzhong
    Shi, Yuanjian
    Ding, Hanlin
    Feng, Yipeng
    Zhang, Te
    Liang, Yingkuan
    Wang, Hui
    Song, Xuming
    Chen, Bing
    Xia, Wenjie
    Mao, Qixing
    Shen, Bo
    Xu, Lin
    Dong, Gaochao
    Jiang, Feng
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2023, 15